# Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

> **NCT05430347** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Neoadjuvant therapy: TCbHPy
- **COMBINATION_PRODUCT:** Neoadjuvant therapy: TCbHP

## Key facts

- **NCT ID:** NCT05430347
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-15
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-09-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430347, "Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05430347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*